CL2007001913A1 - Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias. - Google Patents

Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias.

Info

Publication number
CL2007001913A1
CL2007001913A1 CL2007001913A CL2007001913A CL2007001913A1 CL 2007001913 A1 CL2007001913 A1 CL 2007001913A1 CL 2007001913 A CL2007001913 A CL 2007001913A CL 2007001913 A CL2007001913 A CL 2007001913A CL 2007001913 A1 CL2007001913 A1 CL 2007001913A1
Authority
CL
Chile
Prior art keywords
desloratadine
loratadine
sucralose
povidone
sorbitol
Prior art date
Application number
CL2007001913A
Other languages
English (en)
Inventor
Sergio R Ulloa
Ramos Jose De Jesus Mateo Villacampa
Vargas Luis Javier Juarez
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CL2007001913A1 publication Critical patent/CL2007001913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulación de jarabe antihistamínico que comprende loratadina, desloratadina o una sal de ellas o una combinación de dos o más de las mismas, propilenglicol, sorbitol, citrato de sodio, ácido cítrico, povidona, sucralosa; y uso para tratar y/o prevenir afecciones alérgicas e inflamatorias de la piel o las vías respiratorias.
CL2007001913A 2006-06-29 2007-06-28 Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias. CL2007001913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81731206P 2006-06-29 2006-06-29

Publications (1)

Publication Number Publication Date
CL2007001913A1 true CL2007001913A1 (es) 2008-01-11

Family

ID=38739452

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001913A CL2007001913A1 (es) 2006-06-29 2007-06-28 Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias.

Country Status (18)

Country Link
US (1) US20080262017A1 (es)
EP (1) EP2037921A2 (es)
JP (1) JP2009542665A (es)
KR (1) KR20090024282A (es)
CN (1) CN101505750A (es)
AR (1) AR061668A1 (es)
AU (1) AU2007269835A1 (es)
BR (1) BRPI0713933A2 (es)
CA (1) CA2656087A1 (es)
CL (1) CL2007001913A1 (es)
CO (1) CO6230988A2 (es)
MX (1) MX2009000121A (es)
NO (1) NO20090458L (es)
PE (1) PE20080994A1 (es)
SG (1) SG173333A1 (es)
TW (1) TW200808374A (es)
WO (1) WO2008005267A2 (es)
ZA (1) ZA200900168B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101548959B (zh) * 2008-04-03 2012-11-21 万特制药(海南)有限公司 一种含有地氯雷他定的包衣片剂及其制备方法
WO2011146030A2 (en) * 2010-05-18 2011-11-24 Mahmut Bilgic Effervescent antihistamine formulations
MX346879B (es) 2010-10-21 2017-04-03 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para su uso.
WO2013062497A1 (en) * 2011-10-13 2013-05-02 Mahmut Bilgic Liquid pharmaceutical formulations
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
CN104434789B (zh) * 2014-12-27 2017-04-26 昆明振华制药厂有限公司 一种枸橼酸喷托维林糖浆的制备方法
KR102242382B1 (ko) * 2020-02-28 2021-04-20 삼익제약주식회사 용해성, 안정성 및 쓴맛이 개선된 로라타딘 함유 시럽 조성물
CN113081958B (zh) * 2021-05-01 2022-05-03 安徽新世纪药业有限公司 一种地氯雷他定口服溶液及其制备方法
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
CN114767677B (zh) * 2022-05-06 2023-11-07 成都倍特药业股份有限公司 一种氯雷他定组合物及其制备方法
CN115475141A (zh) * 2022-10-14 2022-12-16 漳州片仔癀药业股份有限公司 一种地氯雷他定口服溶液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
PA8517201A1 (es) * 2000-05-25 2002-08-26 Schering Corp Composiciones farmaceuticas antihistaminicas anticongestivas liquidas estables
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20040101563A1 (en) * 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US7758877B2 (en) * 2004-02-05 2010-07-20 Taro Pharmaceuticals U.S.A., Inc. Stable loratadine spill resistant formulation

Also Published As

Publication number Publication date
CO6230988A2 (es) 2010-12-20
WO2008005267A3 (en) 2008-07-10
AR061668A1 (es) 2008-09-10
NO20090458L (no) 2009-01-28
ZA200900168B (en) 2010-06-30
AU2007269835A1 (en) 2008-01-10
CN101505750A (zh) 2009-08-12
PE20080994A1 (es) 2008-08-06
JP2009542665A (ja) 2009-12-03
US20080262017A1 (en) 2008-10-23
KR20090024282A (ko) 2009-03-06
SG173333A1 (en) 2011-08-29
MX2009000121A (es) 2009-01-26
EP2037921A2 (en) 2009-03-25
BRPI0713933A2 (pt) 2012-12-18
CA2656087A1 (en) 2008-01-10
TW200808374A (en) 2008-02-16
WO2008005267A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
CL2007001913A1 (es) Formulacion de jarabe que comprende loratadina, desloratadina o una sal de la misma, propilenglicol, sorbitol, citrato de sodio citrico, povidona, sucralosa, opcionalmente benzoato de sodio y un acido aminopolicarboxilico; util para tratar alergia e inflamacion de la piel o vias respiratorias.
BRPI1007653A2 (pt) "dispositivos para inalação de insumos medicinais e componentes dos mesmos"
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
DK1986679T3 (da) Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
BR112014000775A2 (pt) curativo de ferimento e método de tratamento
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
BR112012022211A2 (pt) composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto
DK2012763T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID
BRPI0807340A2 (pt) tampões externos (punctal) e métodos de envio de agentes terapêuticos
DK2058317T3 (da) Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens
ITFI20050028A1 (it) Dispositivo, catetere e metodo per il trattamento curativo delle vene varicose
FR2902007B1 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
DK1879654T3 (da) Farmaceutisk kombination af et afsvampningsmiddel og en aktiv substans, som navnlig er eugenol og carvacrol
DK2012764T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
BRPI1007092A2 (pt) "derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato"
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
ITFI20050239A1 (it) Idrossammati come inibitori dell'istone deacetilasi e formulazioni farmaceutiche che li contegono
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
ATE510594T1 (de) Hustenpräparat
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
PE20030721A1 (es) Sales de 4-feniltetrahidroisoquinolinio sustituidas, procedimiento para su preparacion, su uso como medicamentos y medicamento que las contiene